Mismatch repair-deficient tumors with many insertion-deletion mutations and enhanced microsatellite instability responded better to anti-PD-1 immunotherapy.
Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.
Palmetto's MolDx has agreed to cover Myriad's MyPath Melanoma to help rule out the disease when the biopsy can't be definitively classified by standard clinical and histopathological characteristics.
Starting with samples from an 11-year-old boy with spitzoid melanoma, researchers identified recurrent MAP3K8 fusions that may respond to MEK inhibitors.
Biocept will use its liquid biopsy assay to test cerebrospinal fluids of patients diagnosed with certain cancers and then compare results to standard methods.
The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.
Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.
The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.
Investigators are studying samples from a group of 100 patients to try to lock down patterns in circulating tumor DNA that can be used to validate monitoring methods for the clinic.